VIDAZA is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).

Azacitidine Mylan is used for the treatment of adults with the following diseases...myelodysplastic syndromes...

The NCCN Guidelines are based on extensive evaluation of the reviewed risk-based data and indicate current approaches for managing patients with MDS. Five drugs approved by the FDA for treating specific subtypes of MDS include lenalidomide for patients with del(5q) cytogenetic abnormalities; AzaC and decitabine for treating higher-risk or non-responsive patients...

In patients with MDS IPSS INT2 high risk, without major comorbidities and not eligible for alloSCT, azacitidine is recommended...

In a phase III, international, multicentre, controlled, parallel-group, open-label trial, patients with higher-risk myelodysplastic syndromes were randomly assigned one-to-one to receive azacitidine (75 mg/m(2) per day for 7 days every 28 days) or conventional care (best supportive care, low-dose cytarabine, or intensive chemotherapy as selected by investigators before randomisation)....Treatment with azacitidine increases overall survival in patients with higher-risk myelodysplastic syndromes relative to conventional care.